In 2013, energy-based tissue ablation tools and techniques were used in hundreds of millions procedures worldwide, generating an estimated $12.4 billion in cumulative global sales. Cumulative worldwide tissue ablation product sales are projected to register a healthy growth over the forecast period 2015-2020, reaching $16.8 billion in the year 2020.
The scope of market analysis in this major new report – The Future of Tissue Ablation Products to 2020 – covers six primary energy-based tissue ablation technologies: electrosurgical radiofrequency ablation systems; microwave ablation systems; photonic (laser-based) ablation systems; external beam radiation therapy systems; cryogenic ablation systems; and ultrasonic ablation systems.
In 2013, external beam radiotherapy systems accounted for 28.9% of total tissue ablation product revenues, which is the largest market share. Electrosurgical radiofrequency ablation devices accounted for the second largest share at 28.1%, followed by ultrasonic ablation products with 19.8%, medical lasers with 17.4%, cryogenic ablation products with 4.7% and microwave ablation devices with the remaining 1.2%.
Over the forecast period, the largest absolute gains can be expected to occur in the electrosurgical RF ablation product segment thanks to strong growth in barely penetrated AFib ablation businesses. The fastest relative advances are anticipated in microwave and cryogenic ablation product groups.
Figure 1 Tissue Ablation Market Breakdown by Technology Type, 2020 (%)
Source: Smithers Apex
In geographical terms, the Americas contributed the largest share of tissue ablation product sales in 2013 with 41%, followed by the major Western European countries with 28%, major Asian countries segment with 24%, and the rest of the world with 7%. Over the forecast period, the major Asian countries segment is forecast to show the largest absolute increase in tissue ablation dollar volume, gaining over $1.3 billion in corresponding system sales and boosting its relative share in the global marketplace from 24% to 28%. These advances will be driven mostly by the continuing major investments into healthcare infrastructure in China, which is expected to emerge as the second largest medical device market by the end of the forecast period.
Based on extensive primary research, The Future of Tissue Ablation Products to 2020 provides a detailed overview of the technical and clinical characteristics of the key tissue ablation systems, with in-depth analysis of the market dynamics as well as the current and anticipated development pattern for the key tissue ablation product groups.
The Future of Tissue Ablation Products to 2020 is available now for £4,200. For more information, please contact Cherrie Pickard on +44 (0) 1372 802186 or at CPickard@smithers.com